• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Flerie

20.80 SEK-1.42 %10.7, 17.29
Less than 1K followers

FLERIE

NASDAQ Stockholm

Investment

Financials

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.42 %
-1.89 %
-17.46 %
-36.10 %
-36.52 %
-49.42 %
-57.55 %
-83.26 %
-90.94 %

InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent-protected discovery stage substances, so-called DNA-based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.

Read more
Market cap
1.8B SEK
Turnover
901.8K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.8
2026

Extraordinary general meeting '26

15.10
2026

Interim report Q3'26

20.1
2027

Annual report '26

Regulatory press release09.07.2026, 08.00

Flerie AB (publ) Interim Report January – June 2026

Flerie
Regulatory press release08.07.2026, 11.00

Notice of extraordinary general meeting of Flerie AB (publ)

Flerie
Regulatory press release02.07.2026, 08.00

NET ASSET VALUE – 30 June 2026

Flerie

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release30.06.2026, 11.00

Change in the total number of shares and votes in Flerie AB (publ)

Flerie
Regulatory press release26.06.2026, 17.35

Flerie and Biosergen have agreed on a merger plan – Flerie’s first new investment since its listing on Nasdaq Stockholm

Flerie
Press release26.06.2026, 10.00

Flerie portfolio company Bonsai Biotherapeutics receives full approval of clinical trial application for TOL2 in myasthenia gravis

Flerie
Regulatory press release15.06.2026, 10.45

Bulletin from the extraordinary general meeting of Flerie AB (publ) on 15 June 2026 at 10:00 CEST

Flerie
Press release05.06.2026, 10.20

Flerie’s portfolio company Xspray Pharma receives CRL from FDA for Nilopki™

Flerie
Regulatory press release02.06.2026, 08.00

NET ASSET VALUE – 31 May 2026

Flerie
Press release01.06.2026, 13.00

Flerie’s portfolio company Xintela presents positive results from clinical study with its stem cell product XSTEM

Flerie
Regulatory press release29.05.2026, 11.00

Change in the total number of shares and votes in Flerie AB (publ)

Flerie
Press release20.05.2026, 10.00

Flerie’s portfolio company Prokarium presents positive interim data from clinical study in bladder cancer

Flerie
Regulatory press release19.05.2026, 11.00

NOTICE OF EXTRAORDINARY GENERAL MEETING OF FLERIE AB (PUBL)

Flerie
Press release18.05.2026, 12.20

Flerie completes bonus issue resolved by the Annual General Meeting

Flerie
Press release11.05.2026, 08.30

Flerie’s majority owner waives share allocation – other owners’ stake in the company increases by approximately 15.5 per cent

Flerie
Regulatory press release05.05.2026, 08.00

NET ASSET VALUE – 30 April 2026

Flerie
Regulatory press release30.04.2026, 11.00

Change in the total number of shares and votes in Flerie AB (publ)

Flerie
Press release21.04.2026, 16.15

Flerie’s portfolio company Mendus advances clinical program with first patient enrolled in phase 1b trial

Flerie
Regulatory press release15.04.2026, 15.15

The Board of Directors of Flerie has resolved to redeem all Series C shares within the framework of Flerie’s share redemption scheme.

Flerie
Regulatory press release15.04.2026, 08.00

Flerie AB (publ) Interim Report January – March 2026

Flerie